Skip to main content

Drug Interactions between acitretin and Cycrin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

medroxyPROGESTERone acitretin

Applies to: Cycrin (medroxyprogesterone) and acitretin

CONTRAINDICATED: Acitretin interferes with the contraceptive effect of microdosed progestin preparations. The mechanism of interaction has not been described, and it is not known whether the effectiveness of implantable or injectable products are affected.

MANAGEMENT: Because use of acitretin is associated with major birth defects, microdosed 'minipill' progestin preparations are not recommended for women of childbearing potential treated with acitretin. It is not known whether other progestational contraceptives such as implants and injectables offer adequate contraception during acitretin therapy. Simultaneous use of at least two methods of effective contraception is mandatory during acitretin therapy and for at least 3 years after discontinuing therapy. Input from a gynecologist or similar expert on adequate contraception should be sought as needed.

References

  1. Berbis P, Bun H, Geiger JM, Rognin C, Durand a, Serradimigni A, Hartmann D, Privat Y "Acitretin (RO10-1670) and oral contraceptives: interaction study." Arch Dermatol Res 280 (1988): 388-9
  2. "Product Information. Soriatane (acitretin)." Roche Laboratories PROD (2001):

Switch to consumer interaction data

Drug and food interactions

Major

acitretin food

Applies to: acitretin

CONTRAINDICATED: Ethanol consumption with acitretin leads to the formation of etretinate, which has a much longer half-life than acitretin. Major human fetal abnormalities have been associated with the administration of acitretin, etretinate, and other retinoids. The longer elimination half-life of etretinate relative to acitretin increases the duration of teratogenic potential for female patients. In one case report of a patient with apparent sporadic ethanol intake, etretinate was present in plasma and fat for 52 months after acitretin was discontinued.

MANAGEMENT: Female patients should be warned that ethanol is contraindicated during active treatment with acitretin and for two months after cessation of therapy.

References

  1. "Product Information. Soriatane (acitretin)." Roche Laboratories PROD (2001):
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Canadian Pharmacists Association "e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink" (2006):
  4. Cerner Multum, Inc. "Australian Product Information." O 0
View all 4 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer